| 22005 |
Tofacitinib |
Xeljanz® |
For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. |
Rapid Review Complete |
8th March 2022 |
 |
| - |
Tofacitinib |
Xeljanz® |
For the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor). |
Rapid Review Complete |
18th September 2018 |
|
| - |
Tolvaptan |
Jinarc® |
To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease. |
Assessment process complete |
13th September 2018 |
|
| 21028 |
Tralokinumab |
Adtralza® |
For the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy. |
Rapid Review Complete |
29th July 2021 |
|
| - |
Tramadol hydrochloride/dexketoprofen |
Skudexa® |
For the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen. |
Rapid Review Complete |
1st December 2017 |
|
| - |
Trametinib |
Mekinist® |
For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
Assessment process complete |
15th March 2017 |
|
| 22050 |
Trastuzumab deruxtecan |
Enhertu® |
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. |
NCPE Assessment Process Complete |
12th December 2023 |
|
| 23011 |
Trastuzumab deruxtecan |
Enhertu® |
Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. |
NCPE Assessment Process complete |
30th September 2024 |
|
| 24028 |
Trastuzumab deruxtecan |
Enhertu® |
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. |
Rapid Review Complete |
21st August 2024 |
|
| - |
Trastuzumab emtansine |
Kadcyla® |
For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination. |
Assessment process complete |
1st July 2014 |
|
| 20002 |
Trastuzumab emtansine |
Kadcyla® |
As a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. |
Assessment process complete |
12th March 2021 |
|
| 23073 |
Tremelimumab |
Imjudo® |
Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. |
Full HTA submission received from Applicant |
16th July 2024 |
|
| - |
Trientine Tetrahydrochloride (TETA 4HCL) |
Cuprior® |
For the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy. |
Rapid Review Complete |
9th October 2019 |
|
| - |
Trifluridine/tipiracil |
Lonsurf® |
For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. |
Rapid Review Complete |
13th July 2016 |
|
| 22011 |
Trifluridine/tipiracil |
Lonsurf® |
As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. |
Rapid Review Complete |
15th March 2022 |
|
| 24036 |
Dispersible tablet (DT) (dolutegravir sodium, abacavir sulphate, and lamivudine). HTA ID: 24036 |
Triumeq® |
Triumeq® DT is indicated for Human Immunodeficiency Virus type 1 (HIV-1) infection in children of at least three months of age and weighing at least 6 kg to less than 25 kg |
Rapid Review Complete |
18th October 2024 |
|
| 22058 |
Tucatinib |
Tukysa® |
In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
Full HTA submission received from Applicant |
14th March 2024 |
|
| 24008 |
Ublituximab |
Briumvi® |
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. |
Rapid Review Complete |
2nd April 2024 |
|
| - |
Ulipristal acetate |
Esmya® |
For the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
Rapid review complete |
1st June 2016 |
|
| - |
Ulipristal acetate |
Esmya® |
For the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
Rapid review complete |
22nd October 2013 |
|
| - |
Umeclidinium/vilanterol |
Anoro® |
As a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. |
Rapid review complete |
10th July 2014 |
|
| 21039 |
Upadacitinib |
Rinvoq® |
For active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy. |
Rapid review complete |
11th October 2021 |
|
| 21029 |
Upadacitinib |
Rinvoq® |
For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older, who are candidates for systemic therapy. |
Rapid review complete |
29th July 2021 |
|
| 21040 |
Upadacitinib |
Rinvoq® |
For adults with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. |
Rapid review complete |
19th October 2021 |
|
| 19047 |
Upadacitinib |
Rinvoq® |
For the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate. |
Rapid review complete |
10th December 2019 |
|
| 22047 |
Upadacitinib |
Rinvoq® |
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
Rapid review complete |
27th January 2023 |
|
| 23013 |
Upadacitinib |
Rinvoq® |
Upadacitinib (Rinvoq®) is indicated for the treatment of adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
Rapid Review Complete |
26th February 2024 |
|
| - |
Urea |
GlucoRx Allpresan® Diabetic Foam Cream |
For the treatment of dry and sensitive foot skin (Basic) and very dry to chapped foot skin (Intensive) in patients with Diabetes Mellitus. |
Rapid review complete |
25th July 2018 |
|
| - |
Ustekinumab |
Stelara® |
For the treatment of moderate to severe psoriasis. |
Assessment process complete |
8th December 2009 |
|
| - |
Ustekinumab |
Stelara® |
For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist or have medical contraindications to such therapies |
Rapid review complete |
11th January 2017 |
|
| 19048 |
Ustekinumab |
Stelara® |
For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies. |
Rapid review complete |
17th December 2019 |
|
| - |
Vandetanib |
Caprelsa® |
For the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
Rapid review complete |
4th July 2013 |
|
| - |
Vedolizumab |
Entyvio® |
For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. |
Assessment process complete |
13th November 2015 |
|
| - |
Vedolizumab |
Entyvio® |
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. |
Assessment process complete |
13th November 2015 |
|
| 20029 |
Vedolizumab |
Entyvio® |
For subcutaneous administration is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or an anti-TNFα. |
Rapid review complete |
12th August 2020 |
|
| 20030 |
Vedolizumab |
Entyvio® |
For subcutaneous administration is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or an anti-TNFα. |
Rapid review complete |
12th August 2020 |
|
| - |
Velaglucerase Alfa |
VPRIV® |
For long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease. |
Rapid review complete |
20th June 2011 |
|
| - |
Vemurafenib |
Zelboraf® |
For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. |
Assessment process complete |
3rd September 2012 |
|
| - |
Venetoclax |
Venclyxto® |
For the treatment of chronic lymphocytic leukaemia (CLL) |
Rapid review complete |
21st June 2018 |
|
| 22001 |
Venetoclax |
Venclyxto® |
In combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 20046 |
Venetoclax in combination with obinutuzumab |
Venclyxto® / Gazyvaro® |
For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia. |
Assessment process complete |
17th August 2021 |
|
| - |
Venetoclax |
Venclyxto® |
For the treatment of adult patients with CLL who have received at least one prior therapy. |
Assessment process complete |
8th November 2019 |
|
| 21027 |
Vericiguat |
Verquvo® |
For the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy. |
NCPE Assessment Process Complete |
15th July 2021 |
|
| - |
Vernakalant |
Brinavess® |
For haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration. |
Assessment process complete |
4th May 2011 |
|
| - |
Vestronidase alfa |
MEPSEVII® |
For the treatment of non-neurological manifestations of MPS VII. |
Rapid review complete |
22nd May 2019 |
|
| - |
Vismodegib |
Erivedge® |
For the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma. |
Assessment process complete |
22nd January 2014 |
|
| 23003 |
Voclosporin |
Lupkynis® |
Voclosporin is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). |
NCPE assessment ongoing |
5th November 2024 |
|
| 19041 |
Voretigene neparvovec |
Luxturna® |
For the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| - |
Vortioxetine |
Brintellix® |
For the treatment of major depressive episodes in adults. |
Assessment process complete |
18th November 2016 |
|
| 22028 |
Vosoritide |
Voxzogo® |
For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed. |
NCPE Assessment Process Complete |
5th October 2023 |
|
